GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ENDRA Life Sciences Inc (NAS:NDRA) » Definitions » ROA %

ENDRA Life Sciences (ENDRA Life Sciences) ROA % : -81.35% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is ENDRA Life Sciences ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. ENDRA Life Sciences's annualized Net Income for the quarter that ended in Dec. 2023 was $-5.84 Mil. ENDRA Life Sciences's average Total Assets over the quarter that ended in Dec. 2023 was $7.18 Mil. Therefore, ENDRA Life Sciences's annualized ROA % for the quarter that ended in Dec. 2023 was -81.35%.

The historical rank and industry rank for ENDRA Life Sciences's ROA % or its related term are showing as below:

NDRA' s ROA % Range Over the Past 10 Years
Min: -567.48   Med: -154.85   Max: -103.8
Current: -127.25

During the past 10 years, ENDRA Life Sciences's highest ROA % was -103.80%. The lowest was -567.48%. And the median was -154.85%.

NDRA's ROA % is ranked worse than
93.22% of 236 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.85 vs NDRA: -127.25

ENDRA Life Sciences ROA % Historical Data

The historical data trend for ENDRA Life Sciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENDRA Life Sciences ROA % Chart

ENDRA Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -184.82 -147.12 -103.80 -119.00 -125.53

ENDRA Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -121.76 -147.81 -128.65 -147.25 -81.35

Competitive Comparison of ENDRA Life Sciences's ROA %

For the Diagnostics & Research subindustry, ENDRA Life Sciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENDRA Life Sciences's ROA % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's ROA % distribution charts can be found below:

* The bar in red indicates where ENDRA Life Sciences's ROA % falls into.



ENDRA Life Sciences ROA % Calculation

ENDRA Life Sciences's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-10.06/( (9.274+6.754)/ 2 )
=-10.06/8.014
=-125.53 %

ENDRA Life Sciences's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-5.84/( (7.603+6.754)/ 2 )
=-5.84/7.1785
=-81.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


ENDRA Life Sciences  (NAS:NDRA) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-5.84/7.1785
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-5.84 / 0)*(0 / 7.1785)
=Net Margin %*Asset Turnover
=N/A %*0
=-81.35 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


ENDRA Life Sciences ROA % Related Terms

Thank you for viewing the detailed overview of ENDRA Life Sciences's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


ENDRA Life Sciences (ENDRA Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Executives
Michael Milos Thornton officer: Chief Technology Officer 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Anthony Digiandomenico director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Alexander Y Tokman director C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052
Francois Roger Michelon director, officer: Chief Executive Officer 430 N. JUNO LANE, JUNO BEACH FL 33406
Lou Basenese director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Irina Pestrikova officer: Senior Director, Finance 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
David R. Wells officer: Chief Financial Officer 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Michael Harsh director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Longboard Capital Advisors, Llc 10 percent owner 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad 10 percent owner 1312 CEDAR ST., SANTA MONICA CA 90405
Sanjiv Sam Gambhir director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105